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Abstract
Background: A cross sectional study to investigate HPV prevalence according to age and cytology.
Methods: Women presenting to a gynaecological outpatient clinic for a Pap smear test were included in the study
(n=3177). All women had cervical cytology and HPV testing.
Results: Overall prevalence of any 24 HPV type analysed was 33.1% (95% CI 31.5% to 34.7%) and HPV 16 and HPV
42 were the most frequent (6.7% (95% CI 5.8% to 7.6%), 6.8% (95% CI 5.9% to 7.6%)), in total samples. Multiple HPV
infection rate was 12.9% (95% CI 11.8% to 14.1%). High risk HPV (hrHPV) types were present in 27.4% (95% CI 25.8%
to 28.9%) of the samples.
HPV prevalence was highest among 14 to 19 y.o (46.6% (95% CI 40.7%-52.4%)) and second highest among
30–34 y.o. (39.7%, 95% CI 35.4%–44%). HPV 16 was highest among 20–24 (9.0% (95% CI 6.4%–11.6%)) and second
highest among 50 to 54 y.o. (6.3% (95% CI 2.9% to 9.8%).
In Low-grade Squamous Intraepithelial Lesions (LgSIL) cytology samples, the most frequently detected hrHPV types
were: 16 (14.5% (95% CI 12.1% to 16.9%)), 51 (13.0% (95% CI 10.7% to 15.3%)) and 53 (9.1% (95% CI 7.2% to 11.1%))
and in High-grade Squamous Intraepithelial Lesions (HgSIL) were: HPV 16 (37.2% (95% CI 26.5% to 47.9%)), HPV 51
(17.9% (95% CI 9.4% to 26.5%)) and HPV 18 (12.8% (95% CI 5.4% to 20.2%)).
Conclusions: In the population studied, HPV 16 and 51 were the most frequent detected hrHPV types. HPV
positivity, hrHPV and multiple HPV types infections were higher in young women, while HPV prevalence declined
with increasing age and presented two peaks a higher (14–19 y.o.) and a lower one (30–34 y.o.) These results may
contribute to the creation of a national screening programme.
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Background
Overall and age specific distribution of high risk HPV
(hrHPV) and low risk HPV (lrHPV) types data across
geographical regions is crucial for the optimization of
prevention strategies in each country [1-4]. Over 100
types of HPV can infect the anogenital epithelium, but
only 18 types, designated as “oncogenic”, can progress
to severe lesions [5]. Most infections are encountered
by the immune system and regress spontaneously with-
out even been clinically detected. However, in certain
individuals infections persist and if left untreated can lead
to cervical intraepithelial lesions and cervical cancer.
HPV 16 and HPV 18 are the most common oncogenic
types associated with cancer, and are targeted by recently
developed vaccines [6-8]. The “non-oncogenic” HPV
types are associated with hyperplastic lesions such as
genital warts. Infection with a hrHPV is a major contrib-
uting factor in cervical cancer. HPV infection usually
peaks in younger women indicating the age of their first
sexual intercourse while the proportion of HgSIL cases
is higher in middle aged women.
In order to improve the current cervical screening
process, it is essential to combine cytology and HPV test-
ing. Large scale randomized controlled studies need to be
performed to establish the most efficient and cost effective
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cervical cancer screening programme. In Greece there are
limited epidemiological data on HPV prevalence [9-12].
The aim of this study is to describe the prevalence and
age distribution of different HPV types among women
presenting for a Pap smear in an outpatient clinic in
Greece.
Methods
The study group consisted of a consecutive sample of
3177 Caucasian women between 14 and 70 years old
who proceeded to the Outpatient Gynaecological Clinic
of Regional Anticancer Oncology Hospital of Athens “St.
Savvas” (participation rate 67%) and 1st Department of
Obstetrics and Gynaecology, University of Athens, ‘Alex-
andra’ Hospital (participation rate 33%), between January
2007 and November 2010 in order to have their annual
test Pap.
The patients were also offered HPV test with the know-
ledge that it is not part of the screening. Women were eli-
gible if they were no pregnant and had no history of HPV
cervical disease. All patients included in the study have
been only checked once throughout these years. Adequate
specimens had been obtained from all of them, except 7,
which were excluded. All patients included in the study
gave their written informed consent after discussing with
gyneacologists that there would be no implications to their
health. Sexually active adolescents attended either an ado-
lescent health clinic or an adolescent gynecology clinic in
order to have gyneacological tests, such as conventional
genital cultures, and were offered cervical screening and
HPV typing as part of a sexual health prevention protocol.
All adolescents and their guardians gave their written
informed consent prior to being examined after discussing
with gynaecologists that it would have no impact on their
well being. Ethical approval was granted by the ethics
committee of Regional Anticancer Oncology Hospital of
Athens “St. Savvas”.
The studied population was divided into three age groups
according to the biological alterations in women’s repro-
ductive system (14–25 y.o., 26–46 y.o. and 47–70 y.o), in
order to facilitate the recognition of specific differences in
the biological and clinical behaviour of HPV infection
across the years. Cervical cell scrapings were collected by a
gynaecologist with a cytobrush (Rovers Cervex -Brush
Combi Rovers Medical Devices B.V, The Netherlands) from
the ecto- and endo-cervix of the uterus. A slide was pre-
pared for conventional cytology and the cytobrush was
then placed in specimen transport medium (Thin-Prep
PreservCyt Solution Corporate Headquarters: Hologic, Inc.
Ltd.UK) and stored at 4°C until prepared for HPV molecu-
lar analysis. Cytological findings were classified in line with
the 2001 Bethesda classification system. The smears were
submitted to two cytopathologists who worked separately
and the results were discussed. In rare cases of discrepancy
the smear was submitted to the Head of the Cytopathology
department. The Cytopathology department has estab-
lished an internal and also external quality control based
on international external quality assurance tests (Labqual-
ity-Alpha Medical) 5 ml of Thin Prep samples were used
for DNA isolation. They were centrifuged, diluted into lysis
buffer (NucliSENS lysis buffer, bioMérieux Hellas S.A) and
finally subjected to the NucliSENSW easyMAGWplatform
(bioMérieux Hellas S.A) for automated extraction, accord-
ing to manufacturer’s instructions. Nucleic acids were
eluted in 55 μl of elution buffer. DNA quality test was car-
ried out using Human Globin, Beta, Primer set kit (Maxim
Biotech, Inc., South San Francisco, CA) according to man-
ufacturer’s instructions. Aliquots were stored appropriately
for further processing.
The PapilloCheckW HPV-Screening (Greiner Bio-One
GmbH, Germany) was used. This technology is based on
a DNA chip for the type-specific identification of 24
HPV types (high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73, 82 probable high risk 53 and 66 and
low risk: 6, 11, 40, 42, 43, 44/55, 70) [5]. Nucleic acids
were extracted from the cervical scrape preserved in the
ThinPrep. E1 based PCR was performed according man-
ufacturer’s guidelines. For each sample we mixed 19.8 μl
PapilloCheckW MasterMix, 0.2 μl HotStarTaq plus DNA
polymerase (5U/μl, QiagenW) and 5μl DNA from the
cervical sample. Hybridization followed by mixing 30μl
of the PapilloCheckW Hybridization buffer in a fresh re-
action tube with 5 μl of the PCR-product at room
temperature and transferring 25 μl of the hybridization
mix into each compartment of the chip. Positive and
negative controls were used. The chip was incubated for
15 minutes at 25°C temperature in a humid atmosphere
and then washed in 3 solutions, centrifuged and scanned
on the CheckScanner™.
Data were analysed using SAS v9.0. Absolute and relative
frequencies were used to present the HPV types distribu-
tion according to age and cytology. The HPV prevalence
and 95% confidence intervals were calculated using bino-
mial methods and stratified by cytology report and HPV
category. Chi-squared tests were performed to assess statis-
tical significance of any differences in prevalence. 2 × 2
contingency tables Fisher’s exact test was performed along
with Odds Ratio and 95% confidence intervals calculation.
Pearson’s Chi Square test was used in cases of contingency
tables bigger than 2 × 2. Cochran-Armitage test for trend
was used to investigate trend in distribution of certain
types and multiple HPV infection according to escalation
of age. 2-independent samples t-test was used, along with
relevant descriptive statistics (mean value, standard devi-
ation and 95% confidence interval for mean value) to com-
pare average age among patients depending on presence of
specific types and multiple infections. 5% level of statistical
significance and 95% confidence intervals were used.
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Table 1 HPV (HPV+), High Risk HPV (HR+) and multi infection in cytology and age subgroups
Normal ASCUS LSIL HSIL All
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
Total 537 62.6 (59.3–65.8) 10 1.2 (0.4–1.9) 298 34.7 (31.5–37.9) 13 1.5 (0.7–2.3) 858 27.1 (25.5–28.6)
14–25 HPV+ 129 24.0 (20.4–27.6) 7 70 (–) 221 74.2 (69.2–79.1) 13 100 (–) 370 43.1 (39.8–46.4)
Multiple 39 7.3 (5.1–9.5) 2 20 (0–44.8) 115 38.6 (33.1–44.1) 10 76.9 (–) 171 19.9 (17.3–22.6)
HR 107 19.9 (16.5–23.3) 7 70 (–) 199 66.8 (61.4–72.1) 13 100 (–) 326 38 (34.7–41.2)
Total 1226 69.7 (67.5–71.8) 26 1.5 (0.9–2.0) 450 25.6 (23.5–27.6) 58 3.3 (2.5–4.1) 1760 55.5 (53.8–57.3)
26–46 HPV+ 165 13.5 (11.5–15.4) 9 34.6 (16.3–52.9) 342 76 (72.1–79.9) 54 93.1 (–) 570 32.4 (30.2–34.2)
Multiple 39 3.2 (2.2–4.2) 3 11.5 (0–23.8) 148 32.9 (28.5–37.2) 21 36.2 (23.8–48.6) 211 12.0 (10.5–13.5)
HR 111 9.1 (7.4–10.2) 9 34.6 (16.3–52.9) 286 63.6 (59.1–68.0) 49 84.5 (75.2–93.8) 455 25.9 (23.8–27.9)
Total 455 82.4 (79.3–85.6) 17 3.1 (1.6–4.5) 73 13.2 (10.4–16.1) 7 1.3 (0.3–2.2) 552 17.4 (16.1–18.7)
47–70 HPV+ 54 11.9 (8.9–14.8) 2 11.8 (0–27.1) 48 65.8 (54.9–76.6) 5 71.4 (–) 109 19.7 (16.4–23.1)
Multiple 17 3.7 (2.0–5.5) 0 0 14 19.2 (10.1–28.2) 0 0 31 5.6 (3.7–7.5)
HR 41 9.0 (6.4–11.6) 2 11.8 (0–27.1) 39 53.4 (42.0–64.9) 5 71.4 (–) 87 15.8 (12.7–18.8)
Total 2218 70 (68.4–71.6) 53 1.7 (1.2–2.1) 821 25.9 (24.4–27.4) 78 2.5 (1.9–3) 3170 100 (2.5–3.8)
All HPV+ 348 15.7 (14.2–17.2) 18 34 (21.2–46.7) 611 74.4 (71.4–77.4) 72 92.3 (86.4–98.2) 1049 33.1 (31.5–34.7)
Multiple 95 4.3 (3.4–5.1) 5 9.4 (1.6–17.3) 279 34 (30.7–37.2) 30 38.5 (27.7–49.3) 410 12.9 (11.8–14.1)




















The response rate was 62% (3177/5124) and the final sam-
ple consisted of 3170 women with complete cytological
and HPV-DNA testing results. The majority of them were
Greek (2993/3170, 94.4%) and a 5.6% (177/3170) were
Caucasian immigrants living in Greece. Women were 14–
70 years old (mean age 34.2) and were divided according
to their age in three groups: 14-25 (858 women, range 11,
mean 21.2, median 22), 26–46 y.o. (1760 women, range
20, mean 34.6, median 34) and 47-70 y.o (552 women,
range 13, mean 53.0 , median 52). Their cytology results
and distribution by age group are shown in Table 1.
Overall, 1049 of the 3170 (33.1% (95% CI 31.5% to
34.7%)) samples were found to harbour an HPV infection.
We examined HPV prevalence in 5-year periods in order
to assess age trends in relation to HPV infection in more
detail. HPV prevalence exhibited a peak of 46.6% (95% CI
40.7%–52.4%) at 14–19 y.o. and a second peak at the age
group 30-34 y.o. (39.7%, 95% CI 35.4%–44%) which
decreased thereafter (Figure 1). It was also found that the
presence of any HPV genotype was significantly more fre-
quently identified in younger rather than older women
(mean age of HPV positive women 31.2 vs 35.7 for HPV
negative, t test p<0.001).
The overall HPV prevalence in normal, ASCUS, LSIL
and HSIL were 15.7% (95% CI 14.2% to 17.2%, 348/2218),
34% (95% CI 21.2% to 46.7%, 18/53), 74.4% (95% CI 71.4%
to 77.4%, 611/821) and 92.3% (95% CI 86.4% to 98.2%,
72/78), respectively (Table 1). As expected, HPV positivity
was greater in higher grade cytology abnormalities either
in overall or in each age group separately (Pearson’s Chi
Square value p<0.001, Cochran-Armitage trend test p
value p<0.001). Microarrays detected high risk HPV infec-
tion (HR+) in 868 of 3170 women (27.4%, 95% CI 25.8%
to 28.9%). As far as cytology was concerned, the propor-
tion of samples containing at least one of the 17 high risk
types was greater in SIL (LSIL, HSIL 591/899, 65.7% (95%
CI 62.6% to 68.8%)) than in ASCUS (18/53, 34% (95% CI
21.2% to 46.7%) Fisher’s exact test p value p<0.001) or nor-
mal cytology samples (259/2218, 11.7% (95% CI 10.3% to
13%) Fisher’s exact test p value p<0.001).
HPV type distribution
Using the Microarrays method, 24 HPV types were
detected (15 high risk types, 2 probable high risk and 7
low risk). Overall, HPV 16 was the most common high
risk HPV type present with a prevalence of 6.7% (95% CI
5.8% to 7.6%), followed by HPV 51 (5.7%, 95% CI 4.9%
to 6.6%), HPV 53 (3.8%, 95% CI 3.2% to 4.5%), HPV 56
(3.4%, 95% CI 2.7% to 4.0%) and HPV 31 (2.5%, 95% CI
2.0% to 3.1%) (Additional file 1: Table S1).
Within the normal cytology samples, the most common
high risk HPV types identified were 16 (2.6%, 95% CI 2.0%
to 3.3%), 51 (2.5%, 95% CI 1.9% to 3.2%) and 53 (1.8%,
95% CI 1.3% to 2.4%). Among ASCUS cytology samples,
only hrHPV types were detected; HPV 16 was once more
the most frequent type (13.2%, 95% CI 4.1% to 22.3%) fol-
lowed by HPV 51 (9.4%, 95% CI 1.6% to 17.3%) and HPV
45 (5.7%, 95% CI 0 to 11.9%). The three most frequently
detected hr HPV types were 16 (14.5%, 95% CI 12.1% to
16.9%), 51 (13%, 95% CI 10.7% to 15.3%) and 53 (9.1%,
95% CI 7.2% to 11.1%) in LSIL. In HSIL the most common
hrHPV types were 16 (37.2%, 95% CI 26.5% to 47.9%), 51
(17.9%, 95% CI 9.4% to 26.5%) and 18 (12.8%, 95% CI 5.4%
to 20.2%) (Figure 2a).
Regarding the lrHPV types, HPV 42 was the most com-
mon HPV type with an overall prevalence of 6.8% (214,
95% CI 5.9% to 7.6%), followed by HPV 44 (1.9%, 95% CI
1.4% to 2.3%) and HPV 6 (1.6%, 95% CI 1.2% to 2.0%).
These three lrHPV types were detected in this order in
women with normal cytology (3.6% (95% CI 2.8% to 4.4%),
0.9% (95% CI 5.0% to 13.0%) and 0.6% (95% CI 3.0% to
10.0%) respectively). HPV 42 was the most frequent
lrHPV type detected in LSIL (15.6%, 95% CI 13.1% to
18.1%) followed by HPV 6 (4.4%, 95% CI 3.0% to 5.8%)
and HPV 44 (3.8%, 95% CI 2.5% to 5.1%) (Figure 2a).
The age-specific prevalences of HPV types are shown
in Figure 2b. HPV 51 exhibited the highest peak (9.4%,
95% CI 7.5%–11.4%) among the hrHPV types at the age
group 14–25. The prevalence of HPV 51 decreased
thereafter, until the age 26-46. Similarly the peak of HPV
18 prevalence (2.8%, 95% CI 1.7%–3.9%) appeared in the
age group 14–25, and decreased thereafter. Regarding
Figure 1 HPV prevalence (HPV+) in 5-year age groups.
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lrHPV types, HPV 42 was prevalent throughout all ages,
presenting a peak of 9.9% (95% CI 7.9%–11.9%) at the
age group 14–25 and decreasing thereafter until 3.4%
(95% CI 1.9%–5.0%) in women 47–40. The prevalence
peak of HPV 6 (1.9%, 95% CI 1.2%–2.5%) was detected
in the 26–46 years age group, and then dropped until
0.5% (95% CI 0–1.2%) in the 47–70 years age group.
HPV 11 presented equally low percentages in the two
younger groups and did not appear at all in the oldest
women. (Additional file 2: Table S2).
HPV 16 was the most prevalent HPV type in total and
in order to acquire more information regarding its age
distribution we studied it in 5-year age groups. The first
peak appeared at the age group 20–24 (9%, 95% CI
6.4%–11.6%) and HPV 16 prevalence remained relatively
high until the age of 35-39 y.o. and decreased sharply
thereafter. A second peak of 6.3% (95% CI 2.9%–9.8%)
was present at women aged 50–54 y.o and the preva-
lence dropped in older women (Figure 3).
Multiple HPV infection
Multiple HPV infection with either lr or hr HPV types
was found in 12.9% (410/3170, 95% CI 11.8% to 14.1%) of
all samples and 39.1% (410/1049, 95% CI 36.1% to 42%) of
the HPV infected samples (Table 1). The prevalence of
multiple HPV infection was higher in the 14–25 age group
and reduced in older ages. It was also found that the mean
age of multiple HPV infected women (30.1) was lower
than that of single HPV positive women (32.0), a differ-
ence that was statistically significant (t test p=0.036).
Multiple HPV positivity was significantly more com-
mon in SIL (LSIL, HSIL, 309/899, 34.4% (95% CI 31.3%
to 37.5%)) than in ASCUS (5/53, 9.4% (95% CI 1.6% to
17.3%), Fisher’s exact test p value p<0.001) or normal
(95/2218, 4.3% (95% CI 3.4% to 5.1%), Fisher’s exact test
p value p<0.001).
Among women with multiple infections, 66.8% (95% CI
62.3% to 71.4%) were infected with two HPV types; the
most common combination was of 16 with 51, 56 with 66
Figure 2 The relationship between HPV types distribution and cytology (A) and age (B) (with full details given in Additional files 1
and 2).
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and 6 with 42. There were 22.6% (95% CI 18.6% to 26.7%)
of infected women with three HPV types, the most com-
mon combinations of which were 11 with 33 and 45 and
the combination of 16 with 42 and 45. There were also
cases with 4 HPV types (8.3%, 95% CI 5.6% to 11.0%), 5
HPV types (1.4%, 95% CI 0.3% to 2.6%) and 6 HPV types
(1%, 95% CI 0.0% to 1.9%).
Discussion
We present a large study of HPV prevalence in women of
different ages in the area of Athens, from which interest-
ing conclusions can be drawn. As HPV DNA typing is
gradually incorporated in national screening programmes
knowledge of HPV type variations in different geograph-
ical regions is useful information. Similarly, as HPV vac-
cination is introduced as a means of primary cervical
cancer prevention, better prediction models of its efficacy
specific for each area can be made [13].
In our study and in concordance with what is seen in
the general population, normal cytology dominated all
age groups. The highest LgSIL rates appeared among
women aged 14–25 years. Only a minority (1.5%) of
young girls had a high grade lesion and this is again con-
sistent with what is seen in the literature. It also justifies
the current American and British screening programme
that suggest smear testing after the age of 21 and 25
respectively [14,15].
In our study, the HPV prevalence in normal samples
was 15.7%. For Eastern Europe, HPV prevalence in a
meta-analysis of 4053 samples tested with normal cy-
tology was 21.4% [4]. Studies from different regions of
Greece have reported an overall HPV prevalence ranging
from 22.7 to 50.7% [11,12] which is in accordance to our
HPV prevalence of 33.1%. Our findings are also in agree-
ment with other studies in Greece that have suggested a
prevalence of hrHPV ranging between one in five and
one in three. It does however come in stark difference
with what has been reported in another Greek study
conducted by the University of Thessaloniki [10], where
a prevalence of only 2.5% was reported which is among
the lowest ever reported in the world. This difference
might be attributed to the fact that this latter study used
a different HPV identification method.
In an attempt to compare our results with other coun-
tries’ epidemiological data, we presented an age-related
prevalence curve of HPV infection. This curve showed a
peak at the 14–19 age group, a second one at 30–34 y.o.
and then dropped. Although the study by Coupe et al con-
ducted in the Netherlands demonstrated an association
between age and HPV prevalence [16], others have not
identified a significant relation [17]. When we looked spe-
cifically at the age related prevalence of hrHPV, we
observed a peak in the 14–25 years age group, in accord-
ance with other European studies [18,19]. Younger women
are more prone to develop an HPV infection as they tend
to have multiple partners [20] and are also less likely to
have developed immunity to HPV given their recent ex-
posure to the virus.
As expected, HPV prevalence, increased as lesions pro-
gressed to higher grade ones. The same trend was
observed in hrHPV positivity in relation to cytological sta-
tus. Investigating the results per age group, we observed
that hrHPV infection dominated in 14-25 year old women
irrespective of cytology. However young women are less
likely to present cancerous lesions as in the majority of
cases the lesion regresses after 2–3 years [21,22].
Previously, in a 1636 women cohort study conducted
by this group, where the prevalence of subtypes 6, 11,
16, 18, 31 and 33 was tested, HPV 11 was found to be
the most frequent [9]. In the current study, where a
wider range of HPV subtypes were investigated, HPV 16
and 42 were the most frequent (6.7% and 6.8% respect-
ively) in total samples followed by HPV 51 (5.7%). HPV
51 was constantly identified as a common HPV type in
all age groups however its ranking dropped significantly
behind HPV 16 in ages 26–46. A possible explanation
for this may be that HPV 51, although highly prevalent,
is cleared more quickly and possibly causes a more con-
sistent immunologic response with a longer immune
protection conferred to those that have cleared the
virus, making them no longer susceptible to new
infections.
Figure 3 Prevalence curve of hrHPV type 16 in 5-year age groups.
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HrHPV distribution in Mediterranean countries like
Italy, Portugal, Spain [23-26] is similar to our data with
HPV 16 detected first and HPV 51 ranking second or
third. Although HPV 18 prevalence was overall low, its
presence was high (12.8%) among women with high
grade lesions. Generally, the predominance of HPV 16
and 18 in high grade lesions strengthens the importance
of vaccination in prevention of cervical cancer as 50% of
the HSIL lesions in our study harboured infection by
these two types.
Multiple infections were found in 12.9% of Greek popu-
lation. Multiple HPV positivity was more common in
younger women. In addition, women with cervical lesions
had a higher rate of multiple infections compared to those
who had normal cytology. Multiple infections might be a
risk factor for development of cytological abnormalities.
The majority of multi-HPV infected women harboured at
least one hrHPV type and the majority of those carried
two types, which is consistent with other epidemiological
studies [1].
Although this study presented here included a large
number of women of a broad age range, it has some limita-
tions. Our sample is representative of women presenting
for smear testing. However, as smear taking in Greece is
done on an ad hoc basis rather through an organised
screening system, our sample cannot be considered repre-
sentative of the Athenian population. These data may give
us important information regarding regional HPV preva-
lence but large epidemiological studies from different
regions of our country are needed.
Conclusions
HPV 16 and 51 were the most commonly identified
hrHPV types, present in 6.7% and 5.7% overall and 37.2%
and 17.9% in HgSIL cytology samples, respectively. Multi
infection was present in 39.1% of infected cytology sam-
ples. Our results were comparable with what has been
found in other Mediterranean countries.
HPV positivity, hrHPV and multiple HPV types infections
were higher in young women. HPV prevalence declined with
increasing age and presented two peaks a higher (14–19 y.o.)
and a lower one (30–34 y.o.). HPV 16 prevalence remained
high until 35-39 y.o. and presented a second peak in women
aged 50–54 y.o. These results may contribute to the creation
of a national screening programme.
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